Literature DB >> 25593465

Hepatitis B virus infection, diabetes mellitus, and their synergism for cholangiocarcinoma development: a case-control study in Korea.

Ban Seok Lee1, Eun-Cheol Park1, Seung Woo Park1, Chung Mo Nam1, Jaehoon Roh1.   

Abstract

AIM: To identify possible risk factors and their synergism for cholangiocarcinoma development.
METHODS: A hospital-based, case-control study in which we included 276 cholangiocarcinoma patients [193 extrahepatic cholangiocarcinoma (ECC) and 83 intrahepatic cholangiocarcinoma (ICC)], diagnosed at a training hospital in Korea between 2007 and 2013, and 552 healthy controls matched 2:1 for age, sex, and date of diagnosis. Risk factors for cholangiocarcinoma and possible synergism between those factors were evaluated using conditional logistic regression and synergism index, respectively.
RESULTS: There was an association between cholangiocarcinoma and hepatitis B virus (HBV) infection, diabetes mellitus (DM), cholecystolithiasis, choledocholithiasis, and hepatolithiasis, with the adjusted odds ratios (AORs) of 4.1, 2.6, 1.7, 12.4, and 39.9, respectively. Synergistic interaction on the additive model was investigated between HBV infection and DM (AOR = 12.2; 95%CI: 1.9-80.1). In the subgroup analyses, cholecystolithiasis, choledocholithiasis, hepatolithiasis, and DM were significant risk factors for ECC (AOR = 2.0, 18.1, 14.9, and 2.0, respectively), whereas choledocholithiasis, hepatolithiasis, HBV infection, and DM were risk factors for ICC (AOR = 8.6, 157.4, 5.3 and 4.9, respectively). Synergistic interaction was also observed between HBV infection and DM (OR = 22.7; 95%CI: 2.4-214.1). However, there was no synergistic interaction between other significant risk factors for cholangiocarcinoma.
CONCLUSION: In this Korean study, HBV infection and DM were found to exert independent and synergistic effects on the risk for cholangiocarcinoma, including ICC. Exploring the underlying mechanisms for such synergy may lead to the development of cholangiocarcinoma prevention strategies in high-risk individuals.

Entities:  

Keywords:  Cholangiocarcinoma; Diabetes mellitus; Hepatitis; Risk factor; Synergism

Mesh:

Year:  2015        PMID: 25593465      PMCID: PMC4292281          DOI: 10.3748/wjg.v21.i2.502

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  43 in total

1.  The estimation of synergy or antagonism.

Authors:  K J Rothman
Journal:  Am J Epidemiol       Date:  1976-05       Impact factor: 4.897

2.  Diabetes mellitus and increased risk of cholangiocarcinoma: a meta-analysis.

Authors:  Wei Jing; Gang Jin; Xuyu Zhou; Yingqi Zhou; Yijie Zhang; Chenghao Shao; Rui Liu; Xiangui Hu
Journal:  Eur J Cancer Prev       Date:  2012-01       Impact factor: 2.497

Review 3.  Diabetes, oxidative stress, and antioxidants: a review.

Authors:  A C Maritim; R A Sanders; J B Watkins
Journal:  J Biochem Mol Toxicol       Date:  2003       Impact factor: 3.642

Review 4.  Epidemiology of cholangiocarcinoma: an update focusing on risk factors.

Authors:  Hai-Rim Shin; Jin-Kyoung Oh; Eric Masuyer; Maria-Paula Curado; Veronique Bouvard; Yue-Yi Fang; Surapon Wiangnon; Banchob Sripa; Sung-Tae Hong
Journal:  Cancer Sci       Date:  2009-12-04       Impact factor: 6.716

5.  Risk factors for intrahepatic cholangiocarcinoma: a case-control study in China.

Authors:  Yan-Ming Zhou; Zheng-Feng Yin; Jia-Mei Yang; Bin Li; Wen-Yu Shao; Feng Xu; Yu-Lan Wang; Dian-Qi Li
Journal:  World J Gastroenterol       Date:  2008-01-28       Impact factor: 5.742

6.  Synergism of alcohol, diabetes, and viral hepatitis on the risk of hepatocellular carcinoma in blacks and whites in the U.S.

Authors:  Jian-Min Yuan; Sugantha Govindarajan; Kazuko Arakawa; Mimi C Yu
Journal:  Cancer       Date:  2004-09-01       Impact factor: 6.860

7.  Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation.

Authors:  K G Alberti; P Z Zimmet
Journal:  Diabet Med       Date:  1998-07       Impact factor: 4.359

8.  Prevalence of occult hepatitis B virus infection in a general adult population in Korea.

Authors:  Eun Young Song; Yeo Min Yun; Myoung Hee Park; Dong Hee Seo
Journal:  Intervirology       Date:  2009-04-25       Impact factor: 1.763

9.  Hepatitis B virus and intrahepatic cholangiocarcinoma.

Authors:  Nikolaos K Gatselis; Konstantinos Tepetes; Argirios Loukopoulos; Katerina Vasiou; Athanasios Zafiriou; Chrisoula Gioti; Georgios N Dalekos
Journal:  Cancer Invest       Date:  2007-02       Impact factor: 2.176

10.  Activation-induced cytidine deaminase links bile duct inflammation to human cholangiocarcinoma.

Authors:  Junji Komori; Hiroyuki Marusawa; Takafumi Machimoto; Yoko Endo; Kazuo Kinoshita; Tadayuki Kou; Hironori Haga; Iwao Ikai; Shinji Uemoto; Tsutomu Chiba
Journal:  Hepatology       Date:  2008-03       Impact factor: 17.425

View more
  17 in total

Review 1.  Global epidemiology and burden of HCV infection and HCV-related disease.

Authors:  Aaron P Thrift; Hashem B El-Serag; Fasiha Kanwal
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2016-12-07       Impact factor: 46.802

2.  Viral hepatitis B and C infections increase the risks of intrahepatic and extrahepatic cholangiocarcinoma: Evidence from a systematic review and meta-analysis.

Authors:  Jie-Hui Tan; Wan-Yan Zhou; Lei Zhou; Rong-Chang Cao; Guo-Wei Zhang
Journal:  Turk J Gastroenterol       Date:  2020-03       Impact factor: 1.852

3.  Risk Factors for Cholangiocarcinoma After Initial Hepatectomy for Intrahepatic Stones.

Authors:  Ze-Wu Meng; Sheng-Hua Han; Jin-Hai Zhu; Liang-Yi Zhou; Yan-Ling Chen
Journal:  World J Surg       Date:  2017-03       Impact factor: 3.352

4.  Body Mass Index, Diabetes and Intrahepatic Cholangiocarcinoma Risk: The Liver Cancer Pooling Project and Meta-analysis.

Authors:  Jessica L Petrick; Jake E Thistle; Anne Zeleniuch-Jacquotte; Xuehong Zhang; Jean Wactawski-Wende; Alison L Van Dyke; Meir J Stampfer; Rashmi Sinha; Howard D Sesso; Catherine Schairer; Lynn Rosenberg; Thomas E Rohan; Kim Robien; Mark P Purdue; Jenny N Poynter; Julie R Palmer; Christina C Newton; Martha S Linet; Linda M Liao; I-Min Lee; Jill Koshiol; Cari M Kitahara; Jonathan N Hofmann; Barry I Graubard; Edward Giovannucci; Michael J Gaziano; Susan M Gapstur; Neal D Freedman; Dawn Q Chong; Andrew T Chan; Julie E Buring; Laura Beane E Freeman; Peter T Campbell; Katherine A McGlynn
Journal:  Am J Gastroenterol       Date:  2018-09-03       Impact factor: 10.864

5.  Identification of prognostic factors for intrahepatic cholangiocarcinoma using long non-coding RNAs-associated ceRNA network.

Authors:  Zhichen Kang; Lixin Guo; Zhuo Zhu; Rongfeng Qu
Journal:  Cancer Cell Int       Date:  2020-07-16       Impact factor: 5.722

Review 6.  Hepatolithiasis and intrahepatic cholangiocarcinoma: A review.

Authors:  Hyo Jung Kim; Jae Seon Kim; Moon Kyung Joo; Beom Jae Lee; Ji Hoon Kim; Jong Eun Yeon; Jong-Jae Park; Kwan Soo Byun; Young-Tae Bak
Journal:  World J Gastroenterol       Date:  2015-12-28       Impact factor: 5.742

7.  Global trends in intrahepatic and extrahepatic cholangiocarcinoma incidence from 1993 to 2012.

Authors:  Andrea A Florio; Jacques Ferlay; Ariana Znaor; David Ruggieri; Christian S Alvarez; Mathieu Laversanne; Freddie Bray; Katherine A McGlynn; Jessica L Petrick
Journal:  Cancer       Date:  2020-03-04       Impact factor: 6.921

Review 8.  HBV Infection Status and the Risk of Cholangiocarcinoma in Asia: A Meta-Analysis.

Authors:  Hao Zhang; Biqing Zhu; He Zhang; Jianxin Liang; Wenting Zeng
Journal:  Biomed Res Int       Date:  2016-11-23       Impact factor: 3.411

9.  Systematic review and meta-analysis: cholecystectomy and the risk of cholangiocarcinoma.

Authors:  Jianping Xiong; Yaqin Wang; Hanchun Huang; Jin Bian; Anqiang Wang; Junyu Long; Ying Zheng; Xinting Sang; Yiyao Xu; Xin Lu; Haitao Zhao
Journal:  Oncotarget       Date:  2017-07-26

10.  Characteristics and outcomes of cholangiocarcinoma by region in Thailand: A nationwide study.

Authors:  Roongruedee Chaiteerakij; Wirichada Pan-Ngum; Kittiyod Poovorawan; Ngamphol Soonthornworasiri; Sombat Treeprasertsuk; Kamthorn Phaosawasdi
Journal:  World J Gastroenterol       Date:  2017-10-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.